Navigation Links
Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
Date:2/2/2010

About Ricin Toxin

Ricin toxin is a plant toxin thought to be a bioterror threat because of its stability and high potency as well as the large worldwide reservoir created as a by-product of castor oil production. Exposure to ricin results in local tissue necrosis, and general organ failure leading to death within several days of exposure. The potential use of ricin toxin as a biological weapon has been highlighted in an FBI terrorism report, which states that "Ricin and the bacterial agent anthrax are emerging as the most prevalent agents involved in WMD investigations" (http://www.fbi.gov/publications/terror/terrorism2002_2005.pdf).

There are currently no effective means to prevent the effects of ricin intoxication. The successful development of an effective vaccine against ricin toxin may act as a deterrent against the actual use of ricin as a biological weapon and could be used in rapid deployment scenarios in the event of a biological attack. RiVax™ would potentially be added to the Strategic National Stockpile and dispensed in the event of a terrorist attack.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host-Disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
2. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
3. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
4. ISTA Pharmaceuticals Announces Preliminary, Unaudited Revenue of $110.6 Million in 2009
5. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
6. BIA Announces Release of Solis(TM) Integrated ESI Management and E-Discovery Platform
7. Pioneer(R) Surgical Technology, Inc. Announces New Expansion Plan
8. Cardica Announces Fiscal 2010 Second Quarter Financial Results
9. Sequenom Announces Addition to Clinical Advisory Board
10. Omnicell Announces Fourth Quarter and Full-Year 2009 Results
11. Life Spine(R) Announces FDA Clearance of DYNA-LINK(R) Spinal System and PRESIDIO(TM) Spinal Plating System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... , NEW YORK, Oct. 16 Reportlinker.com announces ... in its catalogue. , Reportlinker Adds ... http://www.reportlinker.com/p0155102/Reportlinker-Adds-Allergan-Inc-PharmaVitae-Profile.html , Introduction , This ... Allergan in the Rx pharmaceutical sector. The profile ...
... NEW YORK, Oct. 16 Reportlinker.com ... report is available in its catalogue. ... Middle Eastern Pharmaceutical Market Outlook To ... landscape, growth opportunities , ...
Cached Medicine Technology:Reportlinker Adds Allergan Inc.: PharmaVitae Profile 2Reportlinker Adds Allergan Inc.: PharmaVitae Profile 3Reportlinker Adds Allergan Inc.: PharmaVitae Profile 4Reportlinker Adds Allergan Inc.: PharmaVitae Profile 5Reportlinker Adds Allergan Inc.: PharmaVitae Profile 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities 11
(Date:7/25/2014)... July 25, 2014 As the category creator ... Xoçai is to transform and improve individual lives ... Adam Paul Green a successful Austin, Texas based ... at the end of the July to promote the up ... September 2014. , Eric Worre has been a leader in ...
(Date:7/25/2014)... At World T.E.A.M. Sports’ Adventure Team ... developmentally-disabled teens and young adults discovered that outdoor sporting ... and hiking can be challenging. , The third-year event, ... Chesapeake and Ohio Canal National Historical Park , included ... able-bodied. Under slightly overcast skies and temperatures in the ...
(Date:7/24/2014)... iFitDress.com, a renowned wedding dress manufacturer and retailer, ... party dresses . According to the company’s marketing specialist, ... at discounted prices, up to 59% off. The special ... , Most of the casual party dresses provided ... are popular for special designs, delicate craftsmanship and affordable ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 A few ... Championships but the incredible high jump by Inika McPherson ... this past June, the USATF National Championships hosted the ... Zensah® athlete, Inika McPherson, won US Nationals with the ... new World Record for the biggest height over head ...
(Date:7/24/2014)... tumors, exposure to dim light at night made the ... to data published in Cancer Research , a ... negative effects of dim light exposure on tamoxifen treatment ... the night. , "Resistance to tamoxifen is a growing ... Steven M. Hill, PhD, professor of structural and cellular ...
Breaking Medicine News(10 mins):Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... SAN FRANCISCO, March 27 /PRNewswire/-- CVCTA Education, the ... introduced a new education,program that helps physicians reduce ... (CTA). When properly performed, radiation doses during CTA,are ... amount that has been attributed,to creating a health ...
... The following statement was,issued today by the law firm of ... given that a class action lawsuit was filed in the,United ... all purchasers of securities of NeuroMetrix Inc. (Nasdaq: NURO ... 6,2007, inclusive (the "Class Period")., If you wish to ...
... the American Association for Dental Research, convening this week ... scientists will be part of the Distinguished Lecture Series. ... will feature a Distinguished Lecture designed to interest delegates ... the Stemmons Ballroom at the Hilton Anatole Hotel., ...
... keynote presentations, symposia, and workshops that will anchor the ... Research, convening April 2 at the Hilton Anatole Hotel. ... , Optimizing the Survival of Ceramic ... Scherrer (University of Geneva, Switzerland), 3:15 p.m., Grand Ballroom ...
... most believed,they were not pregnant at the time ... each case., HARRISBURG, Pa., March 27 ... cases reported to the,Pennsylvania Patient Safety Authority in ... not pregnant, according to analysis published in the,Authority,s ...
... GPRO ) announced today that the Company will ... of Molecular Diagnostics Roundtable,Conference" in New York on April ... is scheduled to be webcast live and may be ... Gen-Probe,s website,at http://www.gen-probe.com . The webcast will be ...
Cached Medicine News:Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 4Health News:Eminent scientists to lecture in Dallas 2Health News:Eminent scientists to lecture in Dallas 3Health News:Keynoters, symposia, workshops highlight dental research meeting 2Health News:Keynoters, symposia, workshops highlight dental research meeting 3Health News:Keynoters, symposia, workshops highlight dental research meeting 4Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: